1. Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective. Issue 1 (2nd January 2016) Authors: Gebauer, Niklas; Biersack, Harald; Czerwinska, Ann-Cathrin; Schemme, Janina; Hardel, Tim Tristan; Bernard, Veronica; Rades, Dirk; Lehnert, Hendrik; Luley, Kim Barbara; Thorns, Christoph Journal: Leukemia & lymphoma Issue: Volume 57:Issue 1(2016:Jan.) Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions. Issue 4 (3rd April 2017) Authors: Gurth, Michelle; Bernard, Veronica; Bernd, Heinz-Wolfram; Schemme, Janina; Thorns, Christoph Journal: Leukemia & lymphoma Issue: Volume 58:Issue 4(2017) Page Start: 979 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support. Issue 6 (2nd June 2016) Authors: Gebauer, Niklas; Biersack, Harald; Czerwinska, Ann-Cathrin; Schemme, Janina; Hardel, Tim Tristan; Bernard, Veronica; Rades, Dirk; Lehnert, Hendrik; Luley, Kim Barbara; Thorns, Christoph Journal: Leukemia & lymphoma Issue: Volume 57:Issue 6(2016:Jun.) Page Start: 1482 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗